These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15030283)

  • 41. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.
    Lefkovits J; Plow EF; Topol EJ
    N Engl J Med; 1995 Jun; 332(23):1553-9. PubMed ID: 7739710
    [No Abstract]   [Full Text] [Related]  

  • 42. Starting lipid lowering therapy in the hospital leads to longer-term use, study finds.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Jan; 15(1):8-10. PubMed ID: 14994727
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of antiplatelet inhibitors in peripheral vascular interventions.
    Stavropoulos SW; Shlansky-Goldberg RD
    Semin Intervent Radiol; 2005 Jun; 22(2):80-7. PubMed ID: 21326677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
    Samanen JM; Ali FE; Barton LS; Bondinell WE; Burgess JL; Callahan JF; Calvo RR; Chen W; Chen L; Erhard K; Feuerstein G; Heys R; Hwang SM; Jakas DR; Keenan RM; Ku TW; Kwon C; Lee CP; Miller WH; Newlander KA; Nichols A; Parker M; Peishoff CE; Rhodes G; Ross S; Shu A; Simpson R; Takata D; Yellin TO; Uzsinskas I; Venslavsky JW; Yuan CK; Huffman WF
    J Med Chem; 1996 Dec; 39(25):4867-70. PubMed ID: 8960544
    [No Abstract]   [Full Text] [Related]  

  • 45. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.
    Steinhubl SR
    J Thromb Thrombolysis; 2000 Apr; 9(3):199-205. PubMed ID: 10728017
    [No Abstract]   [Full Text] [Related]  

  • 46. Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs.
    Shlansky-Goldberg R
    J Am Coll Surg; 2002 Jan; 194(1 Suppl):S103-13. PubMed ID: 11800349
    [No Abstract]   [Full Text] [Related]  

  • 47. Gp IIb/IIIa antagonists. Summary and table.
    Coleman SG; Duff R
    Drugs R D; 1999 May; 1(5):371-3. PubMed ID: 10566066
    [No Abstract]   [Full Text] [Related]  

  • 48. FK 633. FR 144633.
    Drugs R D; 1999 May; 1(5):375-6. PubMed ID: 10566067
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in antiplatelet therapy.
    Jneid H; Bhatt DL
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):349-63. PubMed ID: 14661994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
    Verschuren JJ; Trompet S; Wessels JA; Guchelaar HJ; de Maat MP; Simoons ML; Jukema JW
    Eur Heart J; 2012 Jan; 33(2):165-75. PubMed ID: 21804109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiology patient page. Platelets and cardiovascular disease.
    Gregg D; Goldschmidt-Clermont PJ
    Circulation; 2003 Sep; 108(13):e88-90. PubMed ID: 14517153
    [No Abstract]   [Full Text] [Related]  

  • 52. Intelligent platelet inhibitors are on the horizon.
    Gawaz M
    Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1949-50. PubMed ID: 21849701
    [No Abstract]   [Full Text] [Related]  

  • 53. Platelet inhibitors and cardiac surgery.
    Levy JH; Smith PK
    Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S1-2. PubMed ID: 10966003
    [No Abstract]   [Full Text] [Related]  

  • 54. Thrombosis, inflammation, and our evolving understanding of vascular biology during interventional therapy.
    Young JJ
    J Invasive Cardiol; 2006 Jan; 18(1):13-5. PubMed ID: 16391377
    [No Abstract]   [Full Text] [Related]  

  • 55. [Platelet antiaggregants: a review of their indications in primary care].
    Blasco Valle M; Vitoria Lapeña A; Robledo E
    Aten Primaria; 1993 Feb; 11(3):142-6, 148-50. PubMed ID: 8453007
    [No Abstract]   [Full Text] [Related]  

  • 56. Cell adhesion molecules: potential therapeutic and diagnostic implications.
    Mousa SA
    Methods Mol Med; 2004; 93():157-74. PubMed ID: 14733333
    [No Abstract]   [Full Text] [Related]  

  • 57. Applications of anti-platelet monitoring in catheterization laboratory.
    Mukherjee D; Moliterno DJ
    J Thromb Thrombolysis; 2000 Apr; 9(3):293-301. PubMed ID: 10728030
    [No Abstract]   [Full Text] [Related]  

  • 58. Cangrelor: The Paradox of Choice.
    Brar SS
    J Am Coll Cardiol; 2017 Jan; 69(2):186-188. PubMed ID: 28081828
    [No Abstract]   [Full Text] [Related]  

  • 59. Toxins Are an Excellent Source of Therapeutic Agents against Cardiovascular Diseases.
    Koh CY; Modahl CM; Kulkarni N; Kini RM
    Semin Thromb Hemost; 2018 Oct; 44(7):691-706. PubMed ID: 29954012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tetramethylpyrazine in the treatment of cardiovascular and cerebrovascular diseases.
    Guo SK; Chen KJ; Qian ZH; Weng WL; Qian MY
    Planta Med; 1983 Feb; 47(2):89. PubMed ID: 6844454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.